Last Updated: November 16, 2026

Details for Patent: 11,643,397

« Back to Dashboard


Which drugs does patent 11,643,397 protect, and when does it expire?

Patent 11,643,397 protects JESDUVROQ and is included in one NDA.

This patent has thirty-six patent family members in thirty-one countries.

Summary for Patent: 11,643,397
Title:Prolyl hydroxylase inhibitors
Abstract:The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Inventor(s):Kevin J. Duffy, Duke M. FITCH, Jian Jin, Ronggang Liu, Antony N. Shaw, Kenneth Wiggall
Assignee: GlaxoSmithKline LLC
Application Number:US17/383,554
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

US Patent 11,643,397: Claim Scope, Anemia Methods, and HIF-PH Inhibitor Patent Landscape

US Patent 11,643,397 covers a broad class of unsubstituted N-substituted uracil derivatives, plus methods of treating anemia with that class and with the specifically identified compound N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine. The patent has composition-of-matter and method-of-use coverage, but the supplied claims do not establish an approved product, Orange Book listing, patent-term date, assignee, priority chain, prosecution history, or litigation record.

The principal commercial value is in claim 1, which potentially covers a large chemical genus. Claims 3 and 4 are narrower, compound-specific anemia claims. The claims do not recite a dose, route of administration, anemia subtype, treatment duration, patient-selection criterion, or biomarker requirement.

What does US Patent 11,643,397 claim?

The patent claims three related categories:

Claim Subject matter Scope
1 Chemical compound and pharmaceutically acceptable salt Broad Markush genus
2 Method of treating anemia with a claim 1 compound Broad therapeutic-use claim
3 Method of treating anemia with the named compound or its salt Compound-specific use claim
4 Method of treating anemia with the named free compound Narrowest express claim

Claim 1 requires a compound according to formula (I), with:

  • R1 and R4 independently selected from specified hydrocarbyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups;
  • R2 equal to -OR9;
  • R3 equal to hydrogen;
  • R9 equal to hydrogen or a cation;
  • X equal to oxygen;
  • Y equal to oxygen; and
  • R1 and R4 unsubstituted at their carbon and heteroatom positions.

The core is a 1,3-disubstituted, 6-hydroxy-2,4-dioxopyrimidine system bearing a carbonyl-linked glycine-type substituent. The named compound has cyclohexyl groups at the 1- and 3-positions and a glycine carboxylic acid at the 5-position.

What chemical structure does claim 1 cover?

Claim 1 appears directed to a fixed heterocyclic core with variable N-substituents. The core limitations are substantially narrower than the R1/R4 lists.

A simplified structural reading is:

  1. A 1,3-disubstituted 6-hydroxyuracil or uracil-like ring.
  2. A 5-carbonyl substituent linked to an amino-acid-derived group.
  3. A free carboxylic acid or corresponding cationic salt through R9.
  4. Hydrogen at the position designated R3.
  5. Oxygen atoms at X and Y.
  6. Unsubstituted permitted R1 and R4 groups.

The central legal distinction is between the broad list of permitted R1/R4 groups and the additional statement that those groups are unsubstituted. A substituted phenyl, substituted cyclohexyl, halogenated alkyl, or heteroaryl carrying an additional substituent would face a substantial claim-construction issue because the claim expressly requires the relevant carbon or heteroatom of R1 and R4 to be unsubstituted.

Which substituents are potentially included?

The claim expressly lists the following R1 and R4 options:

  • Hydrogen
  • C1-C10 alkyl
  • C2-C10 alkenyl
  • C2-C10 alkynyl
  • C3-C8 cycloalkyl
  • C3-C8 cycloalkyl-C1-C10 alkyl
  • C5-C8 cycloalkenyl
  • C5-C8 cycloalkenyl-C1-C10 alkyl
  • C3-C8 heterocycloalkyl
  • C3-C8 heterocycloalkyl-C1-C10 alkyl
  • Aryl
  • Aryl-C1-C10 alkyl
  • Heteroaryl
  • Heteroaryl-C1-C10 alkyl

The use of "independently" means R1 and R4 need not be identical. The claim therefore potentially covers symmetrical compounds, such as the named dicyclohexyl compound, and unsymmetrical analogues containing two different permitted groups.

The claim does not require R1 and R4 to be cyclohexyl. Cyclohexyl is one embodiment. The broader genus may include acyclic alkyl groups, unsaturated groups, carbocyclic groups, heterocycles, aryl groups, and heteroaryl groups, subject to the unsubstituted limitation.

What does R9 equal?

R9 is hydrogen or a cation. When R9 is hydrogen, the structure contains a carboxylic acid. When R9 is a cation, the claim reaches a salt form.

Potentially relevant salt categories include pharmaceutically acceptable salts formed with alkali metals, alkaline-earth metals, ammonium, or suitable organic amines, although the precise salt universe depends on the patent specification and ordinary pharmaceutical-salt principles. Claim 1 expressly includes a pharmaceutically acceptable salt independently of the R9 language.

How broad is the composition-of-matter protection?

Claim 1 is potentially the strongest claim because it is a composition-of-matter claim. If valid and enforceable, it can reach manufacture, use, sale, or importation of a covered compound without requiring the patent owner to prove that the accused product is used to treat anemia.

The practical scope depends on four issues:

  1. Construction of the formula. The chemical drawing and definitions in the specification control how the shorthand R1-R9, X, and Y are interpreted.
  2. Meaning of the unsubstituted limitation. This may materially reduce the apparent breadth of the Markush groups.
  3. Written description and enablement. A broad genus must be adequately described and enabled across the full claimed substituent space.
  4. Prior art. Uracil derivatives, glycine-linked heterocycles, and hydroxylase inhibitors may be relevant to novelty and obviousness.

The claim is stronger against an exact or near-exact analogue than against a structurally remote anemia therapy. A product containing the named compound or a close salt form presents the clearest literal-infringement risk.

What do claims 2, 3, and 4 protect?

Claim 2: genus-level anemia treatment

Claim 2 covers treating anemia in a human by administering a therapeutically effective amount of any compound falling within claim 1.

The claim does not limit:

  • Chronic kidney disease anemia
  • Anemia associated with myelodysplastic syndromes
  • Chemotherapy-induced anemia
  • Iron-deficiency anemia
  • Anemia of inflammation
  • Anemia caused by hypoxia or impaired erythropoietin signaling
  • Oral or parenteral administration
  • Once-daily or multiple-daily dosing
  • Monotherapy or combination therapy

The absence of a disease-subtype limitation broadens the method claim but may create enablement, written-description, definiteness, or obviousness issues depending on the specification and prosecution history.

Claim 3: named compound and salts

Claim 3 is limited to the identified compound:

N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

and its pharmaceutically acceptable salts.

This claim is narrower than claim 2 but may be commercially important because it directly covers treatment using the likely lead compound. It does not require the compound to be administered in a particular formulation, dosage strength, or route.

Claim 4: named free acid

Claim 4 removes the express salt alternative. It is limited to treatment with the named compound itself.

Claims 3 and 4 create a fallback structure. If the salt language in claim 3 is challenged or construed narrowly, claim 4 preserves an express claim to the free compound. Conversely, claim 4 does not cover a pharmaceutical salt unless the salt is shown to convert to or contain the claimed free compound in a legally relevant manner.

Is US Patent 11,643,397 a drug patent or an HIF-PH inhibitor patent?

The claimed chemistry is consistent with a small-molecule anemia program involving regulation of erythropoiesis, but the supplied claims alone do not identify the pharmacological target, development code, sponsor, or approved drug name.

The claims should not be treated as proof that the compound is an approved hypoxia-inducible factor prolyl hydroxylase inhibitor. That classification requires the patent specification, examples, pharmacology data, regulatory records, or clinical-development materials.

The structural and therapeutic context places the patent near the broader HIF-PH inhibitor field, which includes approved or clinically developed agents such as roxadustat, daprodustat, vadadustat, and molidustat. Those compounds have materially different chemical structures. Structural difference alone does not resolve freedom-to-operate, because patent families may contain genus claims, salt claims, formulation claims, combination claims, or method claims that reach compounds outside a marketed product's primary composition-of-matter patent.

How does this patent compare with major anemia drugs?

Drug or program General class Relationship to US 11,643,397
Roxadustat Oral HIF-PH inhibitor No direct identity shown from the supplied claims
Daprodustat Oral HIF-PH inhibitor No direct identity shown from the supplied claims
Vadadustat Oral HIF-PH inhibitor No direct identity shown from the supplied claims
Molidustat Oral HIF-PH inhibitor No direct identity shown from the supplied claims
Erythropoiesis-stimulating agents Biologic hormones Chemically outside claim 1
Iron products Mineral or iron-repletion therapies Chemically outside claim 1
Transfusion products Blood components Outside claim 1

The patent presents a potential risk primarily for products containing the claimed uracil-based chemistry or close analogues. It does not, based on the supplied claims, directly cover erythropoietin products, iron formulations, transfusion products, or unrelated HIF-PH inhibitor structures.

When does US Patent 11,643,397 lose exclusivity?

The expiration date cannot be determined from the claims alone. US patent expiration generally depends on:

  • The earliest effective nonprovisional filing date;
  • Any continuation or divisional relationship;
  • Patent-term adjustment;
  • Patent-term extension under 35 U.S.C. § 156;
  • Terminal disclaimers;
  • Any applicable patent-term disclaimer or prosecution-history limitation.

For a standard US utility patent, the baseline term is generally 20 years from the earliest effective nonprovisional filing date, subject to statutory adjustments. The issue date, May 2023, does not establish the expiration date. A patent issued in 2023 can expire earlier or later than 2043 depending on its priority chain and term adjustments.[1]

A complete exclusivity timeline also requires separation of:

  1. Patent term;
  2. FDA regulatory exclusivity;
  3. Any orphan-drug exclusivity;
  4. Pediatric exclusivity;
  5. Orange Book-listed patents;
  6. Litigation-related approval restraints.

The claims supplied do not establish any FDA exclusivity period.

What is the Orange Book status of US Patent 11,643,397?

The Orange Book status cannot be established from the claim text. Orange Book listing is tied to an approved new drug application and the sponsor's patent submission, not to patent issuance alone.[2]

A patent may be absent from the Orange Book because:

  • The compound has no approved drug;
  • The patent owner has not listed it;
  • The patent claims do not meet FDA listing criteria;
  • The patent covers an unapproved method;
  • The patent is listed in another regulatory or commercial database instead.

If the claimed compound is not an FDA-approved active ingredient, the patent would not ordinarily create an Orange Book barrier to an ANDA directed to an unrelated approved drug.

Are there Paragraph IV challenges to this patent?

The supplied information does not establish a Paragraph IV notice, ANDA filing, district-court action, or FDA patent-listing dispute involving US 11,643,397.

Paragraph IV risk is most relevant if:

  1. The claimed compound has an approved drug product;
  2. The patent is listed in the Orange Book;
  3. A generic applicant files an ANDA referencing that product;
  4. The applicant certifies that the patent is invalid, unenforceable, or will not be infringed.

For a novel small-molecule anemia product, a generic challenger would likely target the composition claim through one or more of:

  • Anticipation;
  • Obviousness;
  • Lack of written description;
  • Lack of enablement;
  • Indefiniteness;
  • Noninfringement based on a substituted or structurally distinct analogue.

Claims 3 and 4 would be challenged differently. A Paragraph IV applicant could argue that the proposed use does not practice the claimed anemia method, or that the compound is not the claimed free acid or salt. The validity and infringement analysis would depend heavily on the actual proposed product and labeling.

What patent litigation affects US Patent 11,643,397?

No litigation status is established by the supplied material. The patent number and claims do not show whether the patent has been asserted, challenged in an inter partes review, reexamined, terminally disclaimed, or subject to a settlement.

A relevant litigation review would ordinarily examine:

  • Federal district-court complaints;
  • Hatch-Waxman actions;
  • Patent Trial and Appeal Board proceedings;
  • Federal Circuit decisions;
  • ANDA litigation databases;
  • USPTO assignment and maintenance records;
  • FDA Orange Book patent listings.

The absence of litigation information in the claim set means no reliable conclusion can be drawn about enforceability, claim construction, settlement restrictions, or launch timing.

What formulations are protected by this patent?

The supplied claims do not contain a formulation claim. They do not expressly cover:

  • Tablets;
  • Capsules;
  • Immediate-release dosage forms;
  • Extended-release products;
  • Liquid formulations;
  • Injectable formulations;
  • Solid dispersions;
  • Polymorphs;
  • Amorphous forms;
  • Specific excipient combinations;
  • Particle-size distributions;
  • Controlled-release coatings.

A formulation containing the claimed compound could still implicate claim 1 if the active ingredient falls within the claimed structure. That would be infringement based on the compound, not because the patent expressly claims the formulation.

The patent also does not, from the supplied claims, claim a particular salt, crystal form, polymorph, hydrate, solvate, or prodrug. Such protection would require separate claim language.

Does the patent create biosimilar risk?

No material biosimilar issue appears from the supplied claims. The claims cover small molecules, not biologic products.

Biosimilar pathways under the Public Health Service Act apply to biologics. A competing product based on erythropoietin or another biologic would present a separate regulatory and patent analysis. A generic small-molecule product would more likely proceed under an ANDA, assuming an eligible reference listed drug.[3]

What manufacturing and IP barriers does the patent create?

Claim 1 can create a manufacturing barrier if a competitor synthesizes, imports, sells, or uses a covered compound. The claim is not limited to a particular synthetic route. A different manufacturing process may still infringe if the resulting product falls within the claimed structure.

The patent does not, on the supplied claims, cover:

  • A process for making the compound;
  • A specific intermediate;
  • A catalyst;
  • A purification method;
  • A particular crystallization process;
  • A formulation process.

Those barriers would require separate process or manufacturing claims, which may exist elsewhere in the patent family but are not shown here.

The key manufacturing risk is therefore product-based. A design-around strategy would likely focus on changing one or more of:

  • The R1 or R4 substituent;
  • Substitution on those groups;
  • The 6-hydroxy functionality;
  • The 2,4-dioxo pyrimidine core;
  • The carbonyl-glycine linkage;
  • The acid or salt form.

A design-around must account for equivalents doctrine, dependent claims, related patents, and other patent families. A single structural change does not establish freedom to operate.

How strong is the patent estate based on the supplied claims?

Strengths

  • Claim 1 is a composition claim rather than a treatment-only claim.
  • The R1/R4 definitions cover multiple chemical classes.
  • The named compound is expressly included in the method claims.
  • Claim 3 reaches pharmaceutically acceptable salts.
  • Claim 4 preserves coverage of the free compound.
  • The anemia method claims do not limit the anemia subtype or administration route.

Vulnerabilities

  • The broad genus may face written-description and enablement scrutiny.
  • The phrase requiring R1 and R4 to be unsubstituted may narrow practical coverage.
  • Claims 2-4 depend on treatment of anemia and may require proof that the accused use falls within the claim.
  • No formulation, dosage, regimen, manufacturing, polymorph, or combination claim appears in the supplied text.
  • The patent's commercial value depends on whether the compound advanced clinically or received regulatory approval.

What generic launch scenarios exist?

Three launch scenarios are most relevant.

Scenario 1: Exact-compound generic

A generic applicant seeks approval for the named compound or a pharmaceutically acceptable salt. This presents the highest infringement risk under claim 1 and claims 3-4, assuming the product is used for anemia.

Scenario 2: Structural analogue

A competitor develops a close analogue with a different R1 or R4 group. The product may avoid literal infringement if the new group falls outside the claim, especially if it is substituted. Risk remains under claim construction, equivalents, and related patent families.

Scenario 3: Different anemia therapy

A competitor launches a structurally unrelated HIF-PH inhibitor, erythropoiesis-stimulating agent, iron product, or other anemia therapy. The supplied claims do not directly cover that product.

Regulatory timing still depends on approval status, listed patents, regulatory exclusivity, and any separate patents covering the competing compound.

Key Takeaways

  • US Patent 11,643,397 contains one broad composition claim and three anemia-treatment claims.
  • Claim 1 covers a Markush class of 1,3-disubstituted, 6-hydroxy-2,4-dioxopyrimidine derivatives with specified R1 and R4 groups.
  • The named dicyclohexyl compound is expressly covered by claims 3 and 4.
  • Claim 3 includes pharmaceutically acceptable salts; claim 4 is limited to the named free compound.
  • The patent does not, from the supplied claims, include formulation, manufacturing-process, dosage, polymorph, or combination claims.
  • The claims do not establish an FDA approval, Orange Book listing, Paragraph IV challenge, litigation record, license, settlement, or patent expiration date.
  • Biosimilar risk is not material because the claims cover small molecules rather than biologics.
  • The principal freedom-to-operate risk is for the named compound and close analogues within the claim 1 genus.

FAQs

Is US Patent 11,643,397 directed to roxadustat?

The supplied claims do not identify roxadustat, and the claimed named compound is structurally distinct from roxadustat based on the chemical name provided.

Can a substituted cyclohexyl analogue avoid claim 1?

Possibly, because claim 1 requires the relevant carbon or heteroatom of R1 and R4 to be unsubstituted. The final determination depends on the exact substitution pattern and claim construction.

Does claim 3 cover sodium or potassium salts?

Claim 3 expressly covers pharmaceutically acceptable salts. Sodium and potassium salts may fall within that language if they are pharmaceutically acceptable salts of the named compound.

Does the patent cover treatment of chronic kidney disease anemia?

Claim 2 broadly recites treating anemia in a human and does not exclude chronic kidney disease anemia. Whether a particular product label practices the claim depends on the approved or commercial use and the claim's construction.

Can a competitor use a different synthesis route without infringing?

A different synthesis route does not avoid product-by-process liability if the resulting compound falls within claim 1. The supplied claims do not independently recite a manufacturing process.

References

  1. United States Code. (2023). 35 U.S.C. §§ 154, 156.
  2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations.
  3. United States Code. (2023). 21 U.S.C. §§ 355, 262.
  4. U.S. Patent No. 11,643,397, claims 1-4.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,643,397

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Glaxosmithkline JESDUVROQ daprodustat TABLET;ORAL 216951-001 Feb 1, 2023 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y A METHOD OF TREATING ANEMIA ⤷  Start Trial
Glaxosmithkline JESDUVROQ daprodustat TABLET;ORAL 216951-002 Feb 1, 2023 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y A METHOD OF TREATING ANEMIA ⤷  Start Trial
Glaxosmithkline JESDUVROQ daprodustat TABLET;ORAL 216951-003 Feb 1, 2023 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y A METHOD OF TREATING ANEMIA ⤷  Start Trial
Glaxosmithkline JESDUVROQ daprodustat TABLET;ORAL 216951-004 Feb 1, 2023 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y A METHOD OF TREATING ANEMIA ⤷  Start Trial
Glaxosmithkline JESDUVROQ daprodustat TABLET;ORAL 216951-005 Feb 1, 2023 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y A METHOD OF TREATING ANEMIA ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,643,397

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 061570 ⤷  Start Trial
Australia 2007260837 ⤷  Start Trial
Brazil PI0713446 ⤷  Start Trial
Canada 2655491 ⤷  Start Trial
China 101505752 ⤷  Start Trial
Costa Rica 10534 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.